{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:53:51Z","timestamp":1768622031356,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"New Zealand Pharmacy Education and Research Foundation","award":["257"],"award-info":[{"award-number":["257"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ijpharm.2016.04.038","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T06:45:48Z","timestamp":1461912348000},"page":"174-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis"],"prefix":"10.1016","volume":"506","author":[{"given":"Basanth Babu","family":"Eedara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian G.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyamal C.","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2016.04.038_bib0005","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1023\/A:1007568511399","article-title":"Surface composition of spray-dried particles of bovine serum albumin\/trehalose\/surfactant","volume":"17","author":"Adler","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0010","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/med.20140","article-title":"Nanoparticle formulations in pulmonary drug delivery","volume":"29","author":"Bailey","year":"2009","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0015","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1080\/07373937.2013.788509","article-title":"Optimization of spray drying process conditions for the production of maximally viable microencapsulated L. acidophilus NCIMB 701748","volume":"31","author":"Behboudi-Jobbehdar","year":"2013","journal-title":"Dry. Technol."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0168-3659(00)00362-X","article-title":"Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance","volume":"70","author":"Bosquillon","year":"2001","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/jamp.2009.0794","article-title":"Formulations for pulmonary administration of anticancer agents to treat lung malignancies","volume":"24","author":"Carvalho","year":"2011","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0030","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1021\/cg900890n","article-title":"A new insight into pyrazinamide polymorphic forms and their thermodynamic relationships","volume":"10","author":"Castro","year":"2010","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0035","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1021\/cg1004424","article-title":"Pyrazinamide polymorphs: relative stability and vibrational spectroscopy","volume":"10","author":"Cherukuvada","year":"2010","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0032-5910(78)80049-7","article-title":"Moisture bonding in powders","volume":"20","author":"Coelho","year":"1978","journal-title":"Powder Technol."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0045","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.2174\/138161206779026245","article-title":"PEG\u2013lipid micelles for drug delivery","volume":"12","author":"Croy","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0050","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ijpharm.2015.10.019","article-title":"Minimal amounts of dipalmitoylphosphatidylcholine improve aerosol performance of spray-dried temocillin powders for inhalation","volume":"495","author":"Cuvelier","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0055","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2006.02.018","article-title":"Polyethylene glycol phosphatidylethanolamine conjugate (PEG\u2013PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux","volume":"315","author":"Dabholkar","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0060","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1128\/AAC.00217-12","article-title":"Evaluation of a mouse model of necrotic granuloma formation using C3HeB\/FeJ mice for testing of drugs against Mycobacterium tuberculosis","volume":"56","author":"Driver","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0065","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1128\/IAI.70.11.6330-6338.2002","article-title":"In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions","volume":"70","author":"Fenhalls","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0070","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1016\/S0142-9612(02)00182-5","article-title":"New polymeric carriers for controlled drug delivery following inhalation or injection","volume":"23","author":"Fu","year":"2002","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0075","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1021\/mp4006563","article-title":"Inhalable particles containing rapamycin for induction of autophagy in macrophages infected with Mycobacterium tuberculosis","volume":"11","author":"Gupta","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0080","first-page":"1","article-title":"Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment","volume":"6","author":"Hoff","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0085","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jfoodeng.2013.01.003","article-title":"Reducing the deposition of fat and protein covered particles with low energy surfaces","volume":"116","author":"Keshani","year":"2013","journal-title":"J. Food Eng."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0090","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1073\/pnas.0608611104","article-title":"Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus","volume":"104","author":"Lai","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0095","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/jps.20810","article-title":"The relationship between water vapor absorption and desorption by phospholipids and bilayer phase transitions","volume":"96","author":"Mansour","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0100","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ejps.2013.05.012","article-title":"Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer","volume":"49","author":"Meenach","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0105","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ejpb.2008.06.013","article-title":"Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients","volume":"70","author":"Minne","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0110","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2741\/1293","article-title":"The search for new sterilizing anti-tuberculosis drugs","volume":"9","author":"Mitchison","year":"2004","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/pharmaceutics6020333","article-title":"Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers","volume":"6","author":"Muralidharan","year":"2014","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0120","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s11095-009-9957-4","article-title":"Inhaled drug delivery for tuberculosis therapy","volume":"26","author":"Muttil","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijpharm.2013.04.009","article-title":"Spray dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity","volume":"449","author":"Osman","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0130","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijpharm.2013.06.047","article-title":"Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols","volume":"455","author":"Park","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0135","series-title":"Tuberculosis and Nontuberculous Mycobacterial Infections","first-page":"71","article-title":"Chemotherapy of tuberculosis","author":"Patterson","year":"1999"},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0378-5173(02)00359-9","article-title":"The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations","volume":"246","author":"Price","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0150","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/ni.1781","article-title":"Foamy macrophages and the progression of the human tuberculosis granuloma","volume":"10","author":"Russell","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0011108","article-title":"Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach","volume":"5","author":"Ryan","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0160","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1086\/378563","article-title":"Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection","volume":"188","author":"Seiler","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0165","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CDLI.12.3.465-473.2005","article-title":"Glycolipids of Mycobacterium tuberculosis strain H37Rv are potential serological markers for diagnosis of active tuberculosis","volume":"12","author":"Tiwari","year":"2005","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/156720105774370221","article-title":"Lipid-core micelles for targeted drug delivery","volume":"2","author":"Torchilin","year":"2005","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0175","doi-asserted-by":"crossref","first-page":"12001","DOI":"10.1073\/pnas.182233999","article-title":"Trojan particles: large porous carriers of nanoparticles for drug delivery","volume":"99","author":"Tsapis","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0180","series-title":"Global Tuberculosis Report","author":"WHO","year":"2014"},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0185","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1248\/cpb.59.929","article-title":"Optimization and characterization of dry powder of fanhuncaoin for inhalation based on selection of excipients","volume":"59","author":"Yang","year":"2011","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0190","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1211\/jpp.59.7.0003","article-title":"Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method","volume":"59","author":"You","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2016.04.038_bib0195","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int. J. Tuberc. Lung Dis."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316303222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316303222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T06:23:46Z","timestamp":1600496626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517316303222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":39,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0378517316303222"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.04.038","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}